Ionis Provides Improved 2017 Guidance Following Strong Financial Performance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ionis Pharmaceuticals (IONS) PT Raised to $50 at Stifel; Reiterates Hold
August 9, 2017 7:08 AM EDTStifel raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $50.00 (from $42.00) while maintaining a Hold rating following the company's 2Q. IONS reported a net loss of $(0.09)/share, narrowly missing Consensus estimates for $(0.11). Higher-than-estimated revenues of $105M drove most of the beat,... More
Ionis Pharma (IONS) Reports Q2 Loss of $0.09/Share
August 8, 2017 7:11 AM EDTIonis Pharma (NASDAQ: IONS) reported Q2 EPS of ($0.09), versus ($0.47) reported last year. Revenue for the quarter came in at $104.2 million, versus $38.5 million reported last year.
For earnings history and earnings-related data on Ionis Pharma (IONS) click here.
... More